Aging of the world population is a major contributor to the growing prevalence of the metabolic syndrome, as older persons are frequently affected by the constellation of cardiovascular and metabolic risk factors that constitute the syndrome. The metabolic syndrome has been related to the increasing prevalence of obesity, which is escalating even among older age groups. The present review covers data on the novel proposed biological mediators of the metabolic syndrome, which are as well linked to the aging process.
INTRODUCTION
Central obesity and other components of the metabolic syndrome (i.e., hypertension, dyslipidemia, glucose intolerance) are common in older people. Data from the National Health and Nutrition Examination Survey showed that from 2003-2004 to 2011-2012 the prevalence of metabolic syndrome among US adults increased from 32.9 to 34.7% [1 && ]. The prevalence increased from 18.3% among participants aged 20-39 years to 46.7% among those greater than 60 years. In this age group, more than 50% of women and Hispanics had metabolic syndrome [1 && ]. This is worrisome, given the worldwide aging of the population, which may contribute to the rising prevalence of this constellation of cardiovascular and type 2 diabetes (T2D) risk factors and its consequences. Projected data show that by 2030 there will be 8.3 billion people in the world, with 13% aged more than 65 years [2 & ]. Although there is agreement that metabolic syndrome components frequently cluster, much debate exists over its definition, pathogenesis, or clinical efficacy. Since the 1960s several investigators noted that obese patients often have hyperglycemia, hypertension, and hyperuricemia. Ever since, various additional biological mediators have been related to the clustering of risk factors, which is directly related to the accumulation of visceral adiposity in middle-age linked to overeating and sedentarism with deleterious consequences in late life, conceived by Morley as the 'couch potato' syndrome [3] . The present review covers data on the novel proposed biological mediators of metabolic syndrome, which are as well linked to the aging process.
Obesity, sarcopenia, sarcopenic obesity
The prevalence of metabolic syndrome parallels the obesity epidemic, growing also among older populations [2 challenging public health problems. The proportion of overweight (BMI >25 kg/m 2 ) worldwide increased between 1980 and 2013 from 28.8 to 36.9% in men, and from 29.8 to 38.0% in women [4 && ]. Industrialization has enabled the widespread availability of lots of calorie-rich food with little physical efforts, which paradoxically contributed to increased life expectancy in the last century. Excessive nutrition has led to chronic noncommunicable diseases comprising obesity, T2D, and cardiovascular disease (CVD) [ There is evidence suggesting that sarcopenic obesity is associated with greater metabolic disorders and mortality risk than obesity or sarcopenia alone. A prospective study in 4252 participants aged 60-79 years, followed for a mean of 11.3 years, found that all-cause mortality risk was significantly greater in sarcopenic obese men versus nonsarcopenic/nonobese controls, after adjustment for lifestyle characteristics [10 & ]. Proposed mechanisms for sarcopenic obesity include senescent fat macrophages and high-fat diet-related increased oxidative stress and chronic inflammation, possibly resulting in muscle mitochondrial damage by means of reduction in peroxisome proliferator-activated receptor gamma coactivator (PGC)-1a expression [6 & ]. A systematic review compared eight different definitions and found prevalence of sarcopenic obesity ranging 4.4-84% in men and 3.6-94% in women [11] . The lack of agreement on sarcopenic obesity definition and body composition indices and cut-offs entails major research and clinical drawbacks.
A recent proposal states that metabolic syndrome may not be a pathophysiological, rather a physiological process, similar to that occurring in animals as a survival mechanism to avoid starvation in preparation for periods of food shortage [12]. A major difference is that animals become obese prior to a period of fasting (e.g., hibernation, longdistance migration), whereas humans continue to accumulate fat because of continued availability of food. Loss of uricase gene in the past may trigger the thrifty phenotype and predispose to human obesity today [12] . Fructose metabolism results in intracellular ATP depletion with increased uric acid production, increased lipogenesis, and other features of metabolic syndrome. High consumption of fructose-based sweeteners (e.g., soft-sweetened beverages) may have contributed to the increasing prevalence of metabolic syndrome [13 & ]. Another area of debate relates to obese persons without metabolic abnormalities, or metabolically
KEY POINTS
The cluster of T2D and CVD risk factors is prevalent in older populations, which means it will continue to rise with population aging.
Metabolic syndrome is due to central adiposity linked to overeating and sedentarism with deleterious consequences in late life.
Obesity may be complicated with sarcopenia, denoting loss of muscle mass, strength, and quality in older populations.
Relevant biological mediators of metabolic syndrome include sarcopenic obesity, insulin resistance with ectopic fat accumulation, magnesium metabolism alterations, systemic and hypothalamic inflammation, telomere shortening, epigenetics, and circadian rhythm disturbances.
Prevention of obesity and metabolic syndrome is a priority through the promotion of healthier lifestyles and policies for sugar and saturated fats, which might be widely implemented.
healthy obese (MHO). Despite previous conflicting results, a recent study assessing 7122 participants followed by a mean of 17.4 years showed that MHO participants had a higher risk for CVD and T2D versus lean healthy controls and a similar risk for incident CVD as metabolically unhealthy obese [14 & ]. Likewise, a study examining 71 527 persons found that being overweight or obese was a risk factor for myocardial infarction irrespective of metabolic syndrome, which was no more valuable than BMI for risk detection [15 & ].
Insulin resistance in old age
Pathophysiology of metabolic syndrome appears to be largely attributable to insulin resistance with excessive flux of fatty acids implicated. Dietary energy intake exceeding energy expenditure results in spillover of energy storage from adipose tissue to the liver and skeletal muscle. Studies using magnetic resonance spectroscopy have indicated a major role of muscle and liver lipid ectopic accumulation in the pathogenesis of insulin resistance, with muscle insulin resistance promoting nonalcoholic fatty liver disease [7 && ]. Ectopic lipid-induced insulin resistance involves a surplus of intracellular energy in the form of diacylglycerol (DAG), leading to activation of protein kinase u (PKCu) in muscle [16 && ] and PKCe in the liver [17] with consequent impaired insulin signaling. This may help clarify insulin resistance associated with obesity, aging, and glucose intolerance/T2D and the reversal of insulin resistance/ diabetes after weight loss.
Leptin is an important mediator of insulin resistance and not only a marker of adiposity. Higher levels of hepatic gluconeogenesis in various experimental models of diabetes may be attributed to hypoleptinemia with higher rates of macrophageinduced adipocyte lipolysis. These altered metabolic fluxes may be mimicked by lipid infusion and corrected by leptin administration [18] .
An association of insulin resistance with reduced mitochondrial function linked to ectopic fat in muscle and liver has been observed in older adults [19] , supporting the notion that age-associated reduced mitochondrial function contributes to insulin resistance. The age-related reduced mitochondrial ATP production in skeletal muscle has been attributed to cumulative DNA oxidative damage, reduced oxidative phosphorylation capacity, hence insulin resistance [20 & ]. Insulin may promote mitochondrial biogenesis, which may be defective in age-related insulin resistance. Hence, it is difficult to determine whether muscle mitochondrial dysfunction causes or results from insulin resistance.
A key mediator of intracellular energy, nutrient, and oxygen sensing implicated in aging and obesity is the mammal target of rapamycin (mTOR), a protein kinase that phosphorylates serine and threonine, and harmonizes anabolic and catabolic processes for survival. mTOR modulates body weight and food intake through leptin and ghrelin actions at central level, and impacts lipogenesis in different tissues including the liver. It has also been implicated in beta-cell mass expansion and insulin resistance [21] .
The insulin sensitizing adipocytokine adiponectin acts through activation of 5' adenosine monophosphate-activated protein kinase promoting muscle fatty acid oxidation and glucose uptake. It also regulates centrally appetite and energy expenditure. Adiponectin levels and action are reduced in obesity and are extensively investigated as possible targets for obesity therapies [22 & ].
Evidence from cross-sectional and longitudinal studies have shown that diets with high magnesium content are associated with reduced risk of insulin resistance, metabolic syndrome, and T2D. A recent meta-analysis of six studies, including 24 473 participants and 6311 metabolic syndrome cases, confirmed an inverse association of dietary magnesium and metabolic syndrome risk. For every 100-mg/day increment in magnesium intake, metabolic syndrome risk was lowered by 17% [23 & ]. Another meta-analysis based on 13 studies and 5496 participants reported reduced magnesium levels in participants with metabolic syndrome versus controls [24] . A study in older adults with T2D found that total and ionized circulating magnesium concentrations were low and significantly associated with fasting blood glucose and HbA1c, after adjustment for confounders [25 & ]. Interestingly, serum magnesium is an independent correlate of muscle performance in older persons [26] , which may link the role of magnesium in muscle glucose/insulin homeostasis with the risk of sarcopenia and disability in older adults.
Chronic metabolic inflammation
Chronic low-grade systemic inflammation, linked to aging and termed 'inflammaging', may contribute to sarcopenia and its consequences [27 & ]. Adipose tissue can have immune cells and secrete proinflammatory [e.g., tumor necrosis factor (TNF), interleukin (IL)-1b, IL-6] and anti-inflammatory cytokines (adiponectin and IL-10), which may alter insulin sensitivity [28 && ]. Adipose tissue's macrophage infiltration leads to increased cytokinemediated lipolysis and increased rates of hepatic gluconeogenesis by two mechanisms: increased fatty acid delivery to the liver results in increased pyruvate carboxylase activity and hepatic acetyl CoA concentrations through fat oxidation, and greater conversion of glycerol to glucose through a substrate-driven mechanism [7 && ]. In persons with T2D, a global inflammatory score based on plasma cytokines (TNFa, IL-6, MCP-1, osteopontin, fractalkine, and adiponectin) was strongly correlated with insulin resistance quantified by euglycemic clamp Although the link between gut microbiota and obesity is being intensively investigated, human studies are only associations and causation findings in animals have not yet been translated into humans. Clinical trials on microbe-based interventions are starting, because the field began to be explored only a decade ago. There is uncertainty whether changes in microbiota are cause or effect of obesity, and there are still dissimilar results [32] . Differences in genetic background, ethnicity, diet, social behavior, and lifetime antibiotics use may help explain discrepancies.
Fetuin-A is an endogenous ligand for TRL4, which stimulates macrophage migration and activation in a number of animal models of obesity. It has pleiotropic actions and may contribute to insulin resistance [33 & ]. A recent study showed an increase in circulating fetuin-A after only 28-day overfeeding in healthy humans [34] .
Unlike saturated fats, some unsaturated fatty acids may exert anti-inflammatory actions. When omega-6 predominates, proinflammatory leuko-trienes, prostaglandins, prostacyclins, and thromboxanes are produced. Conversely, upon preferential omega-3 availability, the resulting eicosanoids, including new genus of pro-resolvin lipid mediators (i.e., lipoxin, resolvin, protectin, and maresin families), may exert anti-inflamatory actions [35 & ].
Hypothalamic microinflammation
The hypothalamus regulates energy homeostasis, sensing peripheral signals on nutrient stores, and responding through neural signals that control hunger, thermogenesis, and spontaneous activity. 
Longevity, telomeres shortening
Shorter leukocyte telomere length (sTL) is a cellular marker for biological age. Cellular aging may play a role in aging-related diseases via its metabolic effects. A recent study including 2848 participants aged 18-65 years examined the association of sTL with metabolic syndrome trajectories over a 6-year follow-up. There was a significant baseline association of sTL with HDL, waist circumference, triglycerides, and fasting glucose, as well as with the presence and number of metabolic syndrome components, after adjustments for relevant confounders. This association remained significant during 2 or 6-year follow-up [39 & ]. A meta-analysis of 24 studies involving 43 725 participants showed that sTL length was significantly associated with incident coronary heart disease independently of conventional risk factors [40] . Data from the PREDIMED (Prevenció n con Dieta Mediterranea) study showed an improvement of body weight, BMI, waist circumference, and waist/height ratio associated with increased telomere length after a 5- 
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